Your session is about to expire
← Back to Search
Seclidemstat + Azacitidine for Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia
Study Summary
This trial is testing the combination of seclidemstat and azacitidine to treat patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2023 Phase 1 trial • 48 Patients • NCT02038777Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I am not taking medications that are sensitive to changes by certain liver enzymes.I do not have active hepatitis B, hepatitis C, or HIV.I am 18 years old or older.I have had a heart attack in the last 6 months or have uncontrolled heart problems.I am currently pregnant or breastfeeding.I am not taking any strong medication that affects liver enzymes, nor consuming grapefruit or similar fruits.My kidney function is within the normal range or slightly above.I have had a stem cell transplant or am on immunosuppressants due to this procedure within the last 6 months.I have been diagnosed with MDS or CMML.I am willing to use effective birth control during the study.I am not taking any substances that can't be stopped 14 days before starting the trial.I am able to get out of my bed or chair and move around.I have used medications like hydroxyurea or growth factors for blood cell control.My condition did not improve after 6 treatments with specific drugs or it got worse after any number of treatments.I am not currently on any experimental treatments or undergoing chemotherapy, radiotherapy, or immunotherapy.I am not taking strong medication that affects drug transport in the body.I am a woman who can have children and have not had a negative pregnancy test.My liver functions are within the required range.My condition is a type of blood cancer with a certain level of risk or specific genetic changes.My heart's pumping ability is significantly reduced.I have an infection that isn't getting better with antibiotics.My heart's electrical activity (QTcF) is normal and I don't have a family history of sudden death or long QT syndrome.
- Group 1: Treatment (azacitidine, seclidemstat)
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are there previous studies that suggest Seclidemstat is effective?
"As of right now, there are 179 clinical trials underway that are researching Seclidemstat. Out of those179 trials, 33 of them are in Phase 3. Even though a large majority of the studies for Seclidemstat originate from Saint Louis, Missouri, there are 5711 total locations running trials for Seclidemstat."
Are patients currently being signed up for this experimental treatment program?
"That is correct, the listing on clinicaltrials.gov shows that this study requires 44 more patients and is currently open for enrollment at 1 site. The trial was first posted on 7/7/2021 and has been updated 9/21/2022."
How many individuals are currently enrolled in this program?
"That is correct. The clinicaltrials.gov website has the latest information on this trial, which was posted on July 7th, 2021 and updated September 21st, 2022. The study is looking for 44 patients from 1 site."
What condition does Seclidemstat help alleviate?
"Seclidemstat is an effective treatment for malignant neoplasms, 20-30% blasts, and neutropenia and/or thrombocytopenia."
Share this study with friends
Copy Link
Messenger